8-K: Axsome Therapeutics Reports Strong 2023 Revenue Growth and Pipeline Progress

Axsome Therapeutics announced significant revenue growth for 2023, driven by its commercial products Auvelity and Sunosi, and provided updates on its clinical pipeline.

Summary

• Axsome Therapeutics reported a total net product revenue of $204.9 million for the full year 2023, representing a 309% year-over-year increase.
• Auvelity net product sales reached $130.1 million in its first full year of launch, while Sunosi net product revenue was $74.8 million, a 67% year-over-year growth.
• The company's total revenue for 2023 was $270.6 million, including $65.7 million from out-licensing Sunosi in certain ex-U.S. territories.
• Research and development expenses increased to $97.9 million for the full year, primarily due to the advancement of clinical trials and manufacturing costs.
• Selling, general, and administrative expenses rose to $323.1 million, driven by commercialization activities for Auvelity and Sunosi.
• The net loss for the full year was $239.2 million, or $(5.27) per share, which includes $117.9 million in non-cash charges.
• Axsome's cash and cash equivalents totaled $386.2 million at the end of 2023.
• The company anticipates submitting NDAs for AXS-07 in migraine and AXS-14 in fibromyalgia in the first half of 2024.
• Topline results from the SYMPHONY Phase 3 trial in narcolepsy are expected in the first quarter of 2024.
• Topline results from the ADVANCE-2 Phase 3 trial in Alzheimer's disease agitation and the FOCUS Phase 3 trial in ADHD are expected in the second half of 2024.
• Phase 3 trials for solriamfetol in major depressive disorder, binge eating disorder, and shift work disorder are expected to begin in the first quarter of 2024.

Sentiment

Score: 8

Explanation: The document conveys a positive sentiment due to strong revenue growth, successful product launches, and a robust pipeline. However, the significant net loss and increased expenses temper the overall optimism.

Positives

• Axsome experienced substantial revenue growth in 2023, driven by strong sales of Auvelity and Sunosi.
• Auvelity's launch has been successful, with significant sales in its first full year.
• Sunosi continues to show strong growth, both in sales and prescriptions.
• The company has a robust pipeline with multiple late-stage product candidates.
• Axsome has a strong cash position of $386.2 million, which is expected to fund operations into cash flow positivity.
• Payer coverage for Auvelity is stable at approximately 70% of all covered lives.
• Sunosi maintains broad payer coverage in the commercial channel with 95% of lives covered.

Negatives

• The company reported a net loss of $239.2 million for the full year 2023.
• Selling, general, and administrative expenses increased significantly due to commercialization efforts.
• The net loss includes $117.9 million in non-cash charges, including stock-based compensation and contingent consideration expenses.
• The ADVANCE-2 trial completion is now anticipated in the second half of 2024 due to enrollment trends and market dynamics.

Risks

• The company's future success depends on the continued commercial success of Auvelity and Sunosi.
• There are risks associated with the timing and success of ongoing clinical trials.
• The company's ability to obtain regulatory approvals for its product candidates is not guaranteed.
• The company may face challenges in defending its intellectual property.
• Unforeseen circumstances or disruptions to normal business operations could impact results.
• The company's ability to fund additional clinical trials is dependent on its cash position and revenue generation.

Future Outlook

Axsome expects to continue its growth trajectory in 2024, driven by its commercial products and pipeline advancements, with potential NDA submissions and multiple Phase 3 trial readouts anticipated.

Management Comments

• 2023 was a transformational year for Axsome, based on successful commercial execution as well as substantial pipeline advancement and expansion.
• We expect to continue the momentum in 2024 as we drive further growth for our two currently marketed products, and potentially submit two NDAs for migraine and fibromyalgia, read out three Phase 3 trials in narcolepsy, Alzheimers disease agitation, and ADHD, and, in the near term, initiate an equal number of new pivotal trials in depression, binge eating disorder, and shift work disorder.

Industry Context

Axsome's focus on central nervous system disorders aligns with the growing need for innovative treatments in this area, and the company's pipeline addresses several significant unmet medical needs. The company's commercial success with Auvelity and Sunosi positions it as a key player in the CNS therapeutics market.

Comparison to Industry Standards

• Axsome's 309% year-over-year revenue growth significantly exceeds the average growth rate for pharmaceutical companies in the CNS space, which typically ranges from 10-20% for established products.
• The successful launch of Auvelity, with $130.1 million in sales in its first full year, is comparable to other successful novel drug launches in the CNS market, such as Vraylar by AbbVie, which achieved similar sales figures in its initial launch period.
• The company's R&D spending of $97.9 million is in line with other biotech companies at a similar stage of development, such as Sage Therapeutics, which also invests heavily in clinical trials for CNS drugs.
• Axsome's cash position of $386.2 million is relatively strong compared to other companies of similar size, providing a solid foundation for continued operations and clinical development.
• The company's pipeline, with multiple Phase 3 trials underway, is comparable to other companies like Intra-Cellular Therapies, which also has a diverse portfolio of CNS drug candidates.

Stakeholder Impact

• Shareholders will likely react positively to the strong revenue growth and pipeline progress.
• Employees may benefit from the company's growth and expansion.
• Patients may gain access to new treatment options for CNS disorders.
• Suppliers and creditors may see increased business opportunities with the company's growth.

Next Steps

• The company plans to submit NDAs for AXS-07 and AXS-14 in the first half of 2024.
• Topline results from the SYMPHONY trial are expected in the first quarter of 2024.
• Phase 3 trials for solriamfetol in MDD, BED, and SWD are expected to begin in the first quarter of 2024.
• Topline results from the ADVANCE-2 and FOCUS trials are expected in the second half of 2024.
• The company plans to initiate a pivotal Phase 2/3 trial of AXS-05 for smoking cessation in 2024.

Key Dates

Keywords

Axsome Therapeutics, Auvelity, Sunosi, CNS disorders, clinical trials, NDA submission, revenue growth, pharmaceuticals, neuroscience, AXS-05, AXS-07, AXS-12, AXS-14, solriamfetol, Alzheimer's disease, migraine, narcolepsy, fibromyalgia, ADHD, MDD, BED, SWD